- Comparator studies: only ONE study of 31 patients using FOLFIRINOX treatment, Yoshida 2017. You heard that right... the "systematic" lit review covered a single FOLFIRINOX study, but only used this study for the Resection rate comparison. Bizarre. https://www.ncbi.nlm.nih.gov/pubmed/29340058
2005 Conroy comparison is versus metastatic disease. Shouldn't be included. 2008 Chauffert is based on treatment 20 years ago.
The 9-11 month overall survival turned out to be through a secondary source (Hammel, 2016). Why didn't they use that as a primary source as the findings are pertinent and recent. https://www.ncbi.nlm.nih.gov/pubmed/27139057. 442 patients randomised. 16.5 months median OS.
Or why not the recent LAPACT trial release. https://ascopubs.org/doi/abs/10.1200/JCO.2018.36.4_suppl.204. The authors older publications are cited.
Here's a few recent FOLFIRINOX studies to digest https://www.ncbi.nlm.nih.gov/pubmed/30558029 17 months median OS https://ascopubs.org/doi/abs/10.1200/jco.2016.34.4_suppl.408 15.6 months median OS https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5039370/ 14.8 months median OS; 10.3 months median PFS
oh yea... it doesn't fit the company line...
OSL Price at posting:
12.5¢ Sentiment: None Disclosure: Not Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)